Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors
February 24 2025 - 3:16PM
Edgar (US Regulatory)
EXHIBIT 99.1
JOINT FILING AGREEMENT
The undersigned hereby agree that a single Schedule 13G (or any amendment thereto) relating to the common stock of Aardvark Therapeutics, Inc. shall be filed on behalf of each of the undersigned and that this Agreement shall be filed as an exhibit to such Schedule 13G.
Dated: February 24, 2025
Decheng Capital Global Life Sciences Fund IV, L.P.
By:
Decheng Capital Management IV (Cayman), LLC
Its:
General Partner
By:
/s/ Xiangmin Cui
Name: Xiangmin Cui
Title: Manager
Decheng Capital Management IV (Cayman), LLC
By:
/s/ Xiangmin Cui
Name: Xiangmin Cui
Title: Manager
Decheng Capital Global Healthcare Fund (Master), LP
By:
Decheng Capital Global Healthcare GP, LLC
Its:
General Partner
By:
Decheng Capital LLC
Its:
Manager
By:
/s/ Xiangmin Cui
Name: Xiangmin Cui
Title: Manager
Decheng Capital Global Healthcare GP, LLC
By:
Decheng Capital LLC
Its:
Manager
By:
/s/ Xiangmin Cui
Name: Xiangmin Cui
Title: Manager
Xiangmin Cui
/s/ Xiangmin Cui
Aardvark Therapeutics (NASDAQ:AARD)
Historical Stock Chart
From Jan 2025 to Feb 2025
Aardvark Therapeutics (NASDAQ:AARD)
Historical Stock Chart
From Feb 2024 to Feb 2025